Dr. Nishi Suryavanshi Receives Award from ACTG Network

Date: 01/07/2022

Congratulations, Nishi Suryavanshi, recipient of ACTG’s Tuberculosis Transformative Science Group Special Contributions Award.

Study Description A5384 is a trial for people who have or might have tuberculous meningitis (TBM). TBM is an infectious disease...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...